

# Lao People's Democratic Republic

## Tuberculosis profile

Population 2015

6.8 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	3.3 (2–5.1)	49 (29–75)
Mortality (HIV+TB only)	0.25 (0.14–0.39)	3.6 (2–5.7)
Incidence (includes HIV+TB)	12 (8–18)	182 (118–260)
Incidence (HIV+TB only)	0.59 (0.36–0.88)	8.7 (5.3–13)
Incidence (MDR/RR-TB)**	0.76 (0.39–1.1)	11 (5.7–16)

Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.69 (<0.01–1.4)	3.7 (1.1–6.2)	4.4 (1.2–7.5)
Males	1.5 (0.86–2.1)	6.6 (4.4–8.8)	8 (5.2–11)
Total	2.1 (1.4–2.9)	10 (7.4–13)	12 (8–18)

TB case notifications, 2015

Total cases notified	4 638
Total new and relapse	4 534
- % tested with rapid diagnostics at time of diagnosis	37%
- % with known HIV status	90%
- % pulmonary	91%
- % bacteriologically confirmed among pulmonary	85%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	37% (26–57)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.3 (0.16–0.52)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	310	8%
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			280 (190–360)
Estimated % of TB cases with MDR/RR-TB	5.2% (3.1–7.3)	28% (25–30)	
% notified tested for rifampicin resistance	36%	40%	1 689
MDR/RR-TB cases tested for resistance to second-line drugs			14
Laboratory-confirmed cases		MDR/RR-TB: 33, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 33, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	86%	4 198
Previously treated cases, excluding relapse, registered in 2014	61%	23
HIV-positive TB cases, all types, registered in 2014	57%	292
MDR/RR-TB cases started on second-line treatment in 2013	71%	7
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	13%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	42% (38–46)

TB financing, 2016

National TB budget (US\$ millions)	2.9
Funding source: 12% domestic, 88% international, 0% unfunded	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

